BAAR, SWITZERLAND / AGILITYPR.NEWS / March 27, 2026 / SGS, the world’s leading testing, inspection and certification company, is pleased to announce a complimentary webinar titled ‘Supporting ADC Development: From Cell Bank Characterization to Batch Release’, taking place on April 28, 2026.

With demand for antibody-drug conjugates (ADCs) continuing to rise, developers face increasing expectations around analytical rigor, regulatory readiness and life cycle management. Ensuring effective control – from early cell bank characterization to final batch release – is essential for advancing high‑quality, well‑characterized ADCs into clinical and commercial stages.

This expert‑led session will provide a clear, end‑to‑end overview of key development challenges and the regulatory expectations governing ADC programs. Attendees will gain insights into best‑practice analytical strategies, accelerated testing approaches for critical intermediates and the advanced technologies that help strengthen control of critical quality attributes while reducing development risk.

The webinar will also deliver practical guidance to streamline workflows, optimize testing programs and generate robust data to support efficient, compliant progression. Designed for biopharma and pharma professionals working across biologics and antibody‑based therapeutics, it is particularly valuable for analytical development scientists, CMC specialists and QC/QA teams seeking to enhance scientific and operational confidence.

Presented by SGS experts Dr. Richard Adair and Dr. Greg Adams, the session draws on decades of experience in virology, analytical development and biopharmaceutical characterization.

Stakeholders are encouraged to register now to secure their place in this informative webinar.